B-Cancer	0	6	Breast	Breast	NN	B-NP
I-Cancer	7	13	cancer	cancer	NN	I-NP

O	14	17	The	The	DT	B-NP
O	18	27	incidence	incidence	NN	I-NP
O	28	30	of	of	IN	B-PP
B-Cancer	31	37	breast	breast	NN	B-NP
I-Cancer	38	44	cancer	cancer	NN	I-NP
O	45	47	is	be	VBZ	B-VP
O	48	50	no	no	RB	B-ADJP
O	51	57	higher	high	JJR	I-ADJP
O	58	62	than	than	IN	B-PP
O	63	65	in	in	IN	B-PP
O	66	69	the	the	DT	B-NP
O	70	74	rest	rest	NN	I-NP
O	75	77	of	of	IN	B-PP
O	78	81	the	the	DT	B-NP
O	82	92	population	population	NN	I-NP
O	92	93	.	.	.	O

O	94	103	Tamoxifen	Tamoxifen	NN	B-NP
O	104	110	should	should	MD	B-VP
O	111	114	not	not	RB	I-VP
O	115	117	be	be	VB	I-VP
O	118	122	used	use	VBN	I-VP
O	123	125	as	as	IN	B-SBAR
O	126	128	it	it	PRP	B-NP
O	129	132	may	may	MD	B-VP
O	133	139	worsen	worsen	VB	I-VP
O	140	148	symptoms	symptom	NNS	B-NP
O	149	150	[	[	(	O
O	150	152	43	43	CD	B-NP
O	152	153	]	]	)	O
O	153	154	.	.	.	O

O	155	160	Women	Woman	NNS	B-NP
O	161	165	need	need	VBP	B-VP
O	166	170	also	also	RB	B-ADVP
O	171	179	specific	specific	JJ	B-NP
O	180	190	management	management	NN	I-NP
O	191	194	for	for	IN	B-PP
O	195	204	treatment	treatment	NN	B-NP
O	205	207	of	of	IN	B-PP
O	208	211	HAE	HAE	NN	B-NP
O	211	212	.	.	.	O

O	213	218	Short	Short	JJ	B-NP
O	219	223	term	term	NN	I-NP
O	224	235	prophylaxis	prophylaxis	NN	I-NP
O	235	236	:	:	:	O
O	237	242	three	three	CD	B-NP
O	243	250	options	option	NNS	I-NP
O	251	254	are	be	VBP	B-VP
O	255	264	available	available	JJ	B-ADJP
O	264	265	:	:	:	O
O	266	276	attenuated	attenuate	VBN	B-NP
O	277	286	androgens	androgen	NNS	I-NP
O	286	287	,	,	,	O
O	288	298	tranexamic	tranexamic	JJ	B-NP
O	299	303	acid	acid	NN	I-NP
O	304	306	or	or	CC	I-NP
O	307	312	C1Inh	C1Inh	NN	I-NP
O	313	324	concentrate	concentrate	NN	I-NP
O	324	325	.	.	.	O

O	326	331	There	There	EX	B-NP
O	332	334	is	be	VBZ	B-VP
O	335	337	no	no	DT	B-NP
O	338	346	specific	specific	JJ	I-NP
O	347	354	problem	problem	NN	I-NP
O	355	358	for	for	IN	B-PP
O	359	362	the	the	DT	B-NP
O	363	366	use	use	NN	I-NP
O	367	369	of	of	IN	B-PP
O	370	376	theses	theses	DT	B-NP
O	377	382	drugs	drug	NNS	I-NP
O	383	386	for	for	IN	B-PP
O	387	392	short	short	JJ	B-NP
O	393	399	course	course	NN	I-NP
O	400	402	in	in	IN	B-PP
O	403	409	female	female	JJ	B-NP
O	410	418	patients	patient	NNS	I-NP
O	418	419	.	.	.	O

O	420	422	In	In	IN	B-PP
O	423	427	case	case	NN	B-NP
O	428	430	of	of	IN	B-PP
O	431	436	short	short	JJ	B-NP
O	437	441	term	term	NN	I-NP
O	442	453	prophylaxis	prophylaxis	NN	I-NP
O	454	458	with	with	IN	B-PP
O	459	469	attenuated	attenuate	VBN	B-NP
O	470	479	androgens	androgen	NNS	I-NP
O	479	480	,	,	,	O
O	481	483	no	no	DT	B-NP
O	484	496	virilisation	virilisation	NN	I-NP
O	497	500	has	have	VBZ	B-VP
O	501	505	been	be	VBN	I-VP
O	506	514	observed	observe	VBN	I-VP
O	515	516	[	[	(	O
O	516	518	44	44	CD	B-NP
O	518	519	,	,	,	I-NP
O	519	521	45	45	CD	I-NP
O	521	522	]	]	)	O
O	522	523	.	.	.	O

O	524	529	Acute	Acute	JJ	B-NP
O	530	536	attack	attack	NN	I-NP
O	537	546	treatment	treatment	NN	I-NP
O	546	547	:	:	:	O
O	548	553	there	there	EX	B-NP
O	554	556	is	be	VBZ	B-VP
O	557	559	no	no	DT	B-NP
O	560	568	specific	specific	JJ	I-NP
O	569	576	problem	problem	NN	I-NP
O	577	580	for	for	IN	B-PP
O	581	584	the	the	DT	B-NP
O	585	588	use	use	NN	I-NP
O	589	591	of	of	IN	B-PP
O	592	597	C1inh	C1inh	NN	B-NP
O	598	609	concentrate	concentrate	NN	I-NP
O	609	610	,	,	,	O
O	611	621	tranexamic	tranexamic	JJ	B-NP
O	622	626	acid	acid	NN	I-NP
O	626	627	,	,	,	O
O	628	637	icatibant	icatibant	NN	B-NP
O	637	638	;	;	:	O
O	639	641	or	or	CC	O
O	642	653	ecallantide	ecallantide	VB	B-VP
O	654	656	in	in	IN	B-PP
O	657	663	female	female	JJ	B-NP
O	664	672	patients	patient	NNS	I-NP
O	672	673	.	.	.	O

